Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Vast Therapeutics Selected to Present at the American Thoracic Society (ATS) 2024 Respiratory Innovation Summit


MORRISVILLE, N.C., April 17, 2024 /PRNewswire/ -- Vast Therapeutics, a clinical-stage life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases, today announced an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024. Dr. Nathan Stasko, Chief Executive Officer of Vast, will deliver an oral presentation on how its lead candidate, ALX1, is positioned to reshape the treatment landscape for several patient populations chronically infected with Pseudomonas aeruginosa.

Presentation Details:

Session Title: Showcase Two: COVID, Infectious Disease and Other Innovators

Session Date and Time: Saturday, May 18 at 10:15 a.m. PT

Location: Manchester Grand Hyatt San Diego

"ALX1 has dual antimicrobial and anti-inflammatory activity without the concerns of drug resistance and renal toxicity associated with traditional antibiotics," stated Nathan Stasko, Chief Executive Officer of Vast Therapeutics. "A non-intermittent therapy with no 'on-off' periods is desperately needed to sustainably improve the quality of life and decrease the number of hospitalizations experienced by these patients."

More information on the ATS 2024 Respiratory Innovation Summit can be found here.

About Vast Therapeutics
Vast is a life science company focused on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases. This cycle affects patients across the entire spectrum of human life, ranging from children with rare orphan diseases like cystic fibrosis (CF) to adults with non-cystic fibrosis bronchiectasis (NCFB) to the highly prevalent chronic obstructive pulmonary disease (COPD). We believe our product candidates may provide an effective treatment for patients chronically infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes.

Contact:      
Nathan Stasko
Chief Executive Officer
Vast Therapeutics, Inc.
[email protected] 

SOURCE Vast Therapeutics, Inc.


These press releases may also interest you

at 18:00
BetterLife Announces Intent to Complete Private Placement of Units
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...

at 17:48
ANDLAUER HEALTHCARE GROUP ANNOUNCES RESULTS OF VOTING AT ANNUAL MEETING OF SHAREHOLDERS
Andlauer Healthcare Group Inc. ("AHG" or the "Company") announced today the results of voting at its virtual annual meeting of shareholders held on May 3, 2024 (the "Meeting"). All of the nominees listed in the management information circular...

at 17:37
National Institutes of Health All of Us Research Program Mobile Tour Visits California
Starting this week, Little Manilla Rising, University of California, San Francisco, and Community Medical Centers in Stockton, CA will host the All of Us Journey, a traveling educational exhibit that brings the National Institutes of Health's All of...

at 17:28
National Institutes of Health All of Us Research Program Mobile Tour Visits Houston, TX
Starting this week, West Gray Convention Center, National Baptist Convention, Greater Baptist Church, and PRIDENet in Houston, TX will host the All of Us Journey, a traveling educational exhibit that brings the National Institutes of Health's All of...

at 17:25
Non-Surgical Nose Job by Dr. Simon Ourian, A New Nose in 30 Minutes?
In the evolving world of cosmetic procedures, non-surgical nose jobs are marking a significant shift from traditional rhinoplasty, providing a fast, less invasive alternative for...

at 17:15
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's...

More news about Health...


News published on and distributed by: